Treatment of Pulmonary Mucormycosis with Central Nervous System (Brain) Involvement

Clinical scenario

This protocol applies to pulmonary mucormycosis in patients with concurrent central nervous system (brain) involvement by mucormycosis — a severe disease extension that demands rapid, targeted intervention.

Treatment goals

The primary clinical target is stable disease or partial response on imaging, evaluated at regular intervals such as weekly imaging assessments.

First-line approach (overview)

Management combines early complete surgical debridement with immediate antifungal therapy initiated from the outset. CNS involvement informs the specific antifungal choice and the intensity of early treatment.

Full regimen, step-down strategy, and response-guided decision points are in the complete protocol…

Instant Access to Structured Evidence-Based Regimens

References

In CNS involvement, animal models and the above observations support use of liposomal amphotericin B at 10 mg/kg per day.
The guideline group strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment.
There is moderate support for intravenous treatment until stable disease is achieved.

View source ↗